Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany
This year, we are celebrating the 15th anniversary of the first transcatheter aortic valve implantation (TAVI). Several randomised trials paved the way for TAVI which has now become the new standard of care for high and intermediate surgical risk patients with non-inferior outcome compared to surgical aortic valve replacement (SAVR)1,2.
Increasing operator experience, better patient selection, and clinical best practice recommendations have helped to optimise procedural results. However, this development would never have been successful without design modifications of the existing devices and the introduction of so-called next-generation transcatheter heart valves (THV)3.